We develop, validate and implement clinical biomarker assays through our high-complexity CLIA laboratory. We have expertise across a wide range of technology platforms and sample types, with an initial focus on protein biomarkers.
We have also developed a Provider Portal and Testing Operations Software to meet your ordering, accessioning and reporting needs. We have built a cloud-based HIPAA compliant database solution that includes an API interface as well as an HL-7 engine for communicating with partners. Please contact us to discuss your Software needs.
We have the expertise to develop biomarker assays for remote sample collection, and implement the solution in a clinical context - from participant engagement through to data generation. Please contact us to discuss your project.
We also have extensive experience in the development of bioclinical tools to assess disease status in chronic obstructive pulmonary disease (COPD) and other chronic diseases. Learn more about our work.
ProterixBio maintains a rigorous approach to test development that includes collaborating with leading academic medical centers and validating assays in large, carefully curated cohorts.Company Overview
We help develop, validate and implement tests that enable biotech or pharma companies to obtain high-quality protein biomarker data from remote sample collection.Our Platform
Billerica, MA, November 17, 2021: ProterixBio, Inc. (CLIA: 22D2189261) today announced it has received a Clinical Laboratory Permit from New York State Department of Health. This permit enables ProterixBio to…Read More
Billerica, MA, July 1, 2020: ProterixBio, Inc. today announced completing a licensing agreement with the Massachusetts General Hospital for a COVID-19 serology assay. The assay was developed and validated by…Read More